Clinical experience in coronary bypass surgery for abciximab-treated patients

This publication has 15 references indexed in Scilit:

• Emergency coronary artery bypass graft surgery in abciximab-treated patients
  The Annals of Thoracic Surgery, 2000
• Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade
  Circulation, 1998
• An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
  American Heart Journal, 1998
• Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab
  The Journal of Thoracic and Cardiovascular Surgery, 1998
• Abciximab and Excessive Bleeding in Patients Undergoing Emergency Cardiac Operations
  The Annals of Thoracic Surgery, 1998
• Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab
  The American Journal of Cardiology, 1997
• GPIIb/IIIa Antagonists: Pathophysiologic and Therapeutic Insights from Studies of c7E3 Fab
  Thrombosis and Haemostasis, 1997
• Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
  Circulation, 1995
• Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
  The American Journal of Cardiology, 1994
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
  Circulation, 1994